Navigation Links
Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award

JERUSALEM, August 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (, a developer of oral delivery systems, today announced that it is the recipient of the 2009 Frost & Sullivan European Oral Drug Delivery Technology Innovation Award.

Oramed Pharmaceuticals is developing a platform technology to create oral delivery systems for drugs and vaccines delivered via injection. Oramed focuses on the treatment of diabetes through its proprietary flagship product, an Oral Insulin capsule that is currently in Phase 2b clinical trials. Oramed's research pipeline also includes other product candidates, such as an Oral GLP-1 Analog capsule.

"We are honored to receive the 2009 European Oral Drug Delivery Technology Innovation Award," said Nadav Kidron, Esq., Oramed's CEO. "Being recognized for our leadership position in the oral drug delivery field by Frost & Sullivan is an encouraging validation of our progress.

Frost & Sullivan's Technology Innovation Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contact:

    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
4. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
5. SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination
6. Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan
7. Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation
8. Frost & Sullivan: Lower Import Duties and Rising Customer Demand to Boost Russian Electronics Manufacturing Market
9. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
10. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
11. Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ... 24, 2015 , ... This fall, global software solutions leader SAP and AdVenture ... develop and pitch their BIG ideas to improve health and wellness in their schools. ... to win the title of SAP's Teen Innovator, an all-expenses paid trip to Super ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
(Date:10/23/2015)... , October 23, 2015 ... announce a mobile plug and play integration of physiological ... tasks SensoMotoric Instruments (SMI) present a ... solutions for eye tracking and physiological data registration. It ... SMI Eye Tracking Glasses 2w and physiological signals ...
Breaking Biology News(10 mins):